New Stock Issuance - Hai'an Group (Stock Code: 001233) issued at a price of 48.00 on November 14, 2025[1] - Hangzhou Qilun B (Stock Code: 200771) has a cash option declaration period from November 19 to November 25, 2025[1] - Hailianxun (Stock Code: 300277) has a buyback request declaration period from November 12 to November 18, 2025[1] Market Alerts - Pingming Technology (Stock Code: 688109) reported severe abnormal fluctuations on November 13, 2025[1] - ST Yuancheng (Stock Code: 603388) and ST Zhongzhu (Stock Code: 600568) also reported abnormal fluctuations on November 11, 2025[1] - ST Green Kang (Stock Code: 002868) and Dongbai Group (Stock Code: 600693) reported abnormal fluctuations on November 14, 2025[1] Additional Information - Multiple companies including ST Meigu (Stock Code: 000615) and ST Xiangyu (Stock Code: 600107) have ongoing announcements related to stock performance and market conditions[1][2] - The report includes links to detailed announcements for each stock, providing transparency and access to further information for investors[1]

湖南景峰医药股份有限公司 股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 1、湖南景峰医药股份有限公司（以下简称"公司"）于 2025 年 10 月 21 日收到湖南省常德市中级人民法院（以下简称"常德中院"）送达的（2024） 湘 07 破申 7 号《民事裁定书》和（2025）湘 07 破 15 号《决定书》，裁定受 理彭东钜、上海鑫绰投资管理有限公司对公司的重整申请，并指定北京市中伦 律师事务所担任公司管理人。 2、常德中院已裁定公司进入重整程序，公司可能存在因重整失败而被宣 告破产的风险。如果法院裁定公司破产，公司将被实施破产清算，根据《深圳 证券交易所股票上市规则》（以下简称《股票上市规则》）第 9.4.18 条第 （八）项的规定，公司股票将面临被终止上市的风险。 3、公司最近三个会计年度扣除非经常性损益前后净利润孰低者均为负值， 同时，大信会计师事务所（特殊普通合伙）（以下简称"大信"）对公司 2024 年度财务报告出具了带持续经营相关重大不确定性段落的无保留意见的审计报 告。截至本公告披露日，《2024 年年 ...

Group 1 - The flu season in China is expected to peak earlier this year, potentially in late December to early January, due to rising flu activity in southern provinces and different circulating strains compared to last year [4][5]. - The dominant strain this year is expected to be H3N2, which may lead to lower immunity in the population compared to last year's H1N1 strain [5]. - The demand for antiviral medications is anticipated to surge as the flu peak approaches, with several pharmaceutical companies ramping up production [8]. Group 2 - A-share flu-related stocks have shown strong performance, with notable increases in companies such as Weikang Pharmaceutical (+12.08%), Te Yi Pharmaceutical (+10.00%), and Renmin Tongtai (+9.97%) [2][3]. - The flu vaccine and antiviral drug sectors are expected to benefit from the anticipated increase in flu cases, highlighting a dual opportunity for investors in both short-term pandemic catalysts and long-term innovation [8]. - The overall flu-related industry, including vaccine development, infection control, and antiviral drugs, is likely to see a demand surge and value reassessment during the flu season [8].

Core Points - Liu Ting, an independent director of Hunan Jingfeng Pharmaceutical Co., Ltd., has submitted his resignation due to personal reasons [1] - His resignation will result in the independent directors' proportion on the board falling below one-third, and it will take effect after the election of a new independent director at the shareholders' meeting [1] - The board expresses gratitude for Liu Ting's contributions during his tenure [3] Summary by Sections - **Resignation Announcement** - Liu Ting has resigned from his position as an independent director and as the chairman of the remuneration and assessment committee, as well as a member of the nomination committee [1] - His term was originally set to last until the next board election [1] - **Impact on Board Composition** - The resignation will lead to a decrease in the proportion of independent directors on the board, necessitating a prompt election of a new independent director [1] - **Acknowledgment of Contributions** - The board has expressed sincere gratitude for Liu Ting's contributions during his time as an independent director [3]

Core Points - *ST Jingfeng (000908.SZ) announced the resignation of independent director Liu Ting due to personal reasons [1] - Liu Ting will no longer hold any positions within the company after his resignation [1] Company Summary - The board of directors received a written resignation report from independent director Liu Ting [1] - Liu Ting served as the chairman of the remuneration and assessment committee and a member of the nomination committee prior to his resignation [1]

证券代码：000908 证券简称：*ST 景峰 公告编号：2025-085 湖南景峰医药股份有限公司 关于公司独立董事辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 湖南景峰医药股份有限公司（以下简称"公司"）董事会于近日收到独立 董事刘亭先生的书面辞职报告。刘亭先生因个人原因申请辞去公司独立董事及 董事会薪酬与考核委员会主任委员、提名委员会委员职务，辞职后将不再担任 公司任何职务。 刘亭先生原定任期至第八届董事会换届之日止。根据《中华人民共和国公 司法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》《公司章程》等相关规定，刘亭先生的辞职将导致公司独立董事占董事 会成员的比例低于三分之一，刘亭先生的辞职申请将在公司股东大会选举产生 新的独立董事后生效。在此期间，刘亭先生仍将按照相关法律、法规和《公司 章程》的规定继续履行其作为公司独立董事及董事会薪酬与考核委员会主任委 员、提名委员会委员职务。公司董事会将按照相关规定，尽快完成独立董事补 选工作。 截至本公告披露日，刘亭先生未持有公司股份，不存在应当履行而未履行 的承诺事 ...

债券代码：112468 债券简称：16景峰01 摩根士丹利证券（中国）有限公司 关于 湖南景峰医药股份有限公司 2016 年面向合格投资者公开发行公司债券 （第一期） 受托管理事务临时报告 债券受托管理人 （注册地址：中国（上海）自由贸易试验区世纪大道 100 号上海环球金融中心 75 楼 75T30 室） 2025 年 11 月 1 重要声明 摩根士丹利证券（中国）有限公司（以下简称"摩根士丹利证券"）编制本 报告的内容及信息均来源于湖南景峰医药股份有限公司（以下简称"景峰医药"、 "公司"、"发行人"）对外披露的公告及相关公开信息披露文件。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜作出独立判断，而不应将本报告中的任何内容据以作为摩根士丹利证券所作 的承诺或声明。在任何情况下，未经摩根士丹利证券书面许可，不得用作其他任 何用途，投资者依据本报告所进行的任何作为或不作为，摩根士丹利证券不承担 任何责任。 2 摩根士丹利证券作为湖南景峰医药股份有限公司2016年面向合格投资者公 开发行公司债券（第一期）（以下简称"16景峰01"或"本期债券"）的受托管 理人，持续密切关注对该等债 ...

New Stock Issuance - Multiple new stock issuances are scheduled for November 4, 2025, across various companies, including ST Zhongdi (000609) and Pingtan Development (000592) which reported significant abnormal fluctuations[1] - Jiangbolong (301308) and Xiangnong Xinchuan (300475) are among the companies with recent announcements prior to November 4, 2025[1] Abnormal Fluctuations - Pingtan Development (000592) reported severe abnormal fluctuations on November 4, 2025, indicating potential volatility in its stock performance[1] - Other companies such as ST Panda (600599) and ST Huapeng (603021) also reported abnormal fluctuations on the same date, suggesting a trend of instability in the market[1] Market Trends - The report highlights a growing trend of companies experiencing abnormal stock price movements, which may indicate increased market volatility and investor caution[1] - The presence of multiple companies with abnormal fluctuations could signal a broader market trend that investors should monitor closely[1]

Group 1: New Stock Issuances - Multiple new stock issuances are scheduled for October 31, 2025, including Jiangbolong (301308) and Shikong Technology (605178) [1] - A total of 30 companies have announcements related to stock issuance or trading on this date [1] Group 2: Trading Alerts - Jiangbolong (301308) reported severe abnormal fluctuations in trading [1] - Other companies such as ST Wanfang (000638) and Yashichuangneng (603378) also have trading alerts on the same date [1] Group 3: Recent Announcements - Recent announcements include companies like Tianpu Co. (605255) and Kangsheng Co. (002418) with updates on October 31, 2025 [1] - The announcements cover various sectors, indicating a broad market activity [1]

Group 1: Stock Issuance and Trading Alerts - Multiple stocks experienced significant abnormal fluctuations, including 香农芯创 (300475) and 天普股份 (605255) with announcements on October 24 and 21 respectively[1] - 盈新发展 (000620) and *ST宝鹰 (002047) had announcements on October 30 indicating potential trading alerts[1] - A total of 30 stocks were flagged for abnormal trading activities on October 30, indicating a heightened market volatility[1] Group 2: Recent Announcements - 许多公司如 ST万方 (000638) and 农心科技 (001231) had their announcements published on October 27, indicating ongoing corporate activities[2] - The report includes links to detailed announcements for 30 different stocks, providing transparency and access to information for investors[2] - The announcements cover a range of sectors, highlighting the diverse nature of the market and the potential for investment opportunities[2]